MA45532A - Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur - Google Patents

Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur

Info

Publication number
MA45532A
MA45532A MA045532A MA45532A MA45532A MA 45532 A MA45532 A MA 45532A MA 045532 A MA045532 A MA 045532A MA 45532 A MA45532 A MA 45532A MA 45532 A MA45532 A MA 45532A
Authority
MA
Morocco
Prior art keywords
onest
vortioxetine
rapid
intended
antidepressant effect
Prior art date
Application number
MA045532A
Other languages
English (en)
Inventor
Benny Bang-Andersen
Connie Sanchez Morillo
Karina Krøjer Søby
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59239917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45532(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA45532A publication Critical patent/MA45532A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045532A 2016-07-01 2017-06-28 Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur MA45532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357722P 2016-07-01 2016-07-01

Publications (1)

Publication Number Publication Date
MA45532A true MA45532A (fr) 2019-05-08

Family

ID=59239917

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045532A MA45532A (fr) 2016-07-01 2017-06-28 Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur

Country Status (17)

Country Link
US (4) US9820984B1 (fr)
EP (1) EP3478289A1 (fr)
JP (1) JP2019524682A (fr)
KR (1) KR20190025556A (fr)
CN (1) CN109310691A (fr)
AU (1) AU2017288456A1 (fr)
BR (1) BR112018003930A2 (fr)
CA (1) CA3026728A1 (fr)
CL (1) CL2018003707A1 (fr)
CO (1) CO2018013792A2 (fr)
IL (1) IL263584A (fr)
MA (1) MA45532A (fr)
MX (1) MX2018015759A (fr)
RU (1) RU2018144248A (fr)
SG (1) SG11201810644TA (fr)
TW (1) TW201806599A (fr)
WO (1) WO2018002115A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45532A (fr) * 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MX2008016008A (es) 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
MY150647A (en) 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
RS53539B1 (sr) 2009-04-24 2015-02-27 H. Lundbeck A/S Tečne formulacije soli 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina
CA2769872A1 (fr) 2009-08-24 2011-03-03 H. Lundbeck A/S Nouvelles compositions de 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
MX344144B (es) 2012-01-03 2016-12-07 H Lundbeck As Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)feni l] piperazina.
US9211288B2 (en) 2012-12-13 2015-12-15 H. Lundbeck A/S Compositions comprising vortioxetine and donepezil
HRP20170607T1 (hr) 2013-02-22 2017-06-30 H. Lundbeck A/S Proizvodni postupak vortioksetina
CA2933733A1 (fr) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Utilisation d'un antagoniste du recepteur opioide presentant une activite kappa et de vortioxetine dans le traitement de trouble depressif avec caracteristiques melancoliques
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
MA45532A (fr) * 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur

Also Published As

Publication number Publication date
CA3026728A1 (fr) 2018-01-04
US9913839B2 (en) 2018-03-13
JP2019524682A (ja) 2019-09-05
SG11201810644TA (en) 2018-12-28
BR112018003930A2 (pt) 2018-09-25
CN109310691A (zh) 2019-02-05
WO2018002115A1 (fr) 2018-01-04
US20200030319A1 (en) 2020-01-30
KR20190025556A (ko) 2019-03-11
EP3478289A1 (fr) 2019-05-08
MX2018015759A (es) 2019-03-21
CO2018013792A2 (es) 2019-01-18
IL263584A (en) 2019-01-31
US10258617B2 (en) 2019-04-16
AU2017288456A1 (en) 2018-12-13
RU2018144248A (ru) 2020-08-03
US20180000815A1 (en) 2018-01-04
TW201806599A (zh) 2018-03-01
US9820984B1 (en) 2017-11-21
US20180153881A1 (en) 2018-06-07
CL2018003707A1 (es) 2019-02-15

Similar Documents

Publication Publication Date Title
HUE057795T2 (hu) Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
EP3353696A4 (fr) Détection d'agents pathogènes utilisant un séquençage de nouvelle génération
MA42924A (fr) Variants optimisés d'anticorps anti-vegf
HUE047477T2 (hu) Palbociclib szilárd dózisformái
MA46180A (fr) Analogues de l'amyline
EP3277381C0 (fr) Dérivés de nitrobenzyle d'agents anticancéreux
EP3274440A4 (fr) Détection de troubles de l' sophage
EP3556343A4 (fr) Composition de type huile dans l'eau
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
DK3488443T3 (da) Udvælgelse af neoepitoper som sygdomsspecifikke mål for terapi med øget virkning
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
EP3314503A4 (fr) Simulation d'une application
EP3250367A4 (fr) Étalonnage d'agent
IL262852A (en) Treatment of complement-mediated disorders
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
EP3397617A4 (fr) Inhibiteurs de l'histone déméthylase
EP3484854A4 (fr) Inhibiteurs de l'apoptose
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
MA49152A (fr) Schémas posologiques d'immunoconjugués anti-cd33
EP3355893A4 (fr) Composition synergique pour le maintien d'un équilibre sain de la microflore
EP3459369A4 (fr) Composition pharmaceutique utilisant la souchelactobacillus
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine